Page 149 - Genomic Testing News Today

A discussion on clinical considerations for genomic testing in patients with early-stage breast cancer.

A comprehensive overview of genomic assays conducted for patients with early-stage breast cancer including MammaPrint, BluePrint, Oncotype DX.

The country’s health regulations rightfully prioritize patient safety, but innovation is being lost

Cancers? indie when we are more prone to developing cancers? ~ ., when we are more prone to developing cancers? ~ . ., , , when we are more prone to developing cancers? . . , , , cancers? we are really lucky because in the nhs in — cancers? we are really lucky because in the nhs in england _ cancers? we are really lucky because in the nhs in england we _ cancers? we are really lucky because in the nhs in england we now - cancers? we are really lucky because in the nhs in england we now have i ...

Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

Dr Kettle provide insights into unmet needs surrounding treatment of metastatic breast cancer.

With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.

/PRNewswire/ -- Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced...